Medical signs

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

Retrieved on: 
Monday, August 2, 2021
Biotechnology, General Health, Hospitals, Health, Pharmaceutical, Branches of biology, Biology, Life sciences, Glycoproteomics, Proteomics, Biomarkers, Biotechnology, Chemical pathology, Medical signs, Precision medicine

InterVenn Biosciences today announced the completion of a $201 million Series C financing.

Key Points: 
  • InterVenn Biosciences today announced the completion of a $201 million Series C financing.
  • To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications.
  • InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine.
  • For more information about InterVenn Biosciences, please visit the companys website .

Mental Health Symptoms on the Rise Among the Visually Impaired

Retrieved on: 
Friday, July 30, 2021
Ophthalmology, Branches of biology, Vision, Gerontology, Visual impairment, Macular degeneration, Geriatrics, Ageing, Macula of retina, Medical signs, AMD Alliance International

New studies now indicate that mental health symptoms among those with vision loss are being diagnosed five times higher than the national average.

Key Points: 
  • New studies now indicate that mental health symptoms among those with vision loss are being diagnosed five times higher than the national average.
  • As baby boomers age and face age-related diseases such as macular degeneration, the incidence of vision loss or blindness is expected to double by 2050.
  • Geriatricians and behavioral health experts agree that among this aging population vision loss has risen to the forefront as a public health concern.
  • Hadley recently launched its new online learning platform, Hadley.edu , built on many months of research and development and based on the needs, wants and desires of visually impaired adults.

$1.3 Billion Worldwide Intracranial Pressure (ICP) Monitoring Devices Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 29, 2021
Infectious diseases, Health, Medical devices, Branches of biology, Neurotrauma, Medical signs, Intracranial pressure, Neurophysiology, Ventricular system, ICP

The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Intracranial Pressure (ICP) Monitoring Devices estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
  • Invasive, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$1.7 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $365 Million, While China is Forecast to Grow at 8.1% CAGR
    The Intracranial Pressure (ICP) Monitoring Devices market in the U.S. is estimated at US$365 Million in the year 2020.

NEC's artificial intelligence (AI) supports doctors to determine if colorectal lesions are potentially neoplastic

Retrieved on: 
Wednesday, July 14, 2021
Clinical medicine, Medicine, Medical specialties, Medical signs, Gynaecology, Polyp, Colorectal cancer, Neoplasm

TOKYO, July 14, 2021 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic.

Key Points: 
  • TOKYO, July 14, 2021 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic.
  • NEC developed a new technology, called "Cx20," while seeking to assist in the early detection of colorectal lesions.
  • The software then becomes an extra tool immediately available to assist endoscopists in the differentiation of lesions and reduces the burden on patients.
  • Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures.

NEC’s Artificial Intelligence (AI) Supports Doctors to Determine If Colorectal Lesions Are Potentially Neoplastic

Retrieved on: 
Wednesday, July 14, 2021
Other Manufacturing, Technology, Medical devices, Photography, Manufacturing, Audio, Video, Software, Health, Oncology, Clinical medicine, Medicine, Medical specialties, Medical signs, Gynaecology, Polyp, Colorectal cancer, Neoplasm, Large intestine

NEC Corporation (NEC; TOKYO: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic.

Key Points: 
  • NEC Corporation (NEC; TOKYO: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic.
  • NEC developed a new technology, called Cx20, while seeking to assist in the early detection of colorectal lesions.
  • View the full release here: https://www.businesswire.com/news/home/20210714005377/en/
    The Cx20 function supports the identification of disease: During examinations, suspected lesions are automatically detected through video taken by endoscope devices.
  • Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures.

New Clinical Study Investigates Using Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients

Retrieved on: 
Friday, July 9, 2021
Oncology, Health, Medical devices, Surgery, Genetics, Radiology, Clinical trials, Branches of biology, Clinical medicine, Medicine, Hepatology, Medical signs, Biotechnology, Biomarkers, Chemical pathology, Hepatocellular carcinoma, Cancer, Liver cancer

Participants with primary or secondary liver cancer will be recruited from Hampshire Hospitals NHS Foundation Trust in Basingstoke .

Key Points: 
  • Participants with primary or secondary liver cancer will be recruited from Hampshire Hospitals NHS Foundation Trust in Basingstoke .
  • Perspectum will also partner with experts in clinical applications of genomic sequencing in patients with cancer from the University of Oxford .
  • In the study, Perspectums Hepatica imaging technology will be integrated with clinically actionable whole genome sequencing biomarkers and digital pathology results to disrupt the cancer care pathway.
  • Mr Rees adds, This could represent another key step towards personalised care for patients with both primary and secondary cancer in the liver.

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Biology, Medical signs, Biomarkers, Neurotrauma, Biotechnology, Chemical pathology

DoD/MTEC previously awarded $1.9 million to Ischemix to fund preclinical research on CMX-2043 for TBI.

Key Points: 
  • DoD/MTEC previously awarded $1.9 million to Ischemix to fund preclinical research on CMX-2043 for TBI.
  • The successful preclinical efficacy results were achieved in measures of recognized blood biomarkers, MRI analysis and behavior.
  • We are excited to commence this important phase of the development of our proprietary drug candidate to treat TBI.
  • The Center for Disease Control reports that in the US in 2014, there were about 2.9 million TBI-related emergency department visits.

Nighttime Snacking Market Soars Past $50 Billion, with Nightfood Set to Take Center Stage

Retrieved on: 
Tuesday, June 15, 2021
Branches of biology, Clinical medicine, Medical specialties, Digestive system, Milk, Medical signs, Bloating, Gynaecology, Oncology, Melatonin, Sleep, Lactose

Pioneering growth-stage company breaks new ground at intersection of two massive health categories: nutrition and sleep.

Key Points: 
  • In addition, Nightfood's team of leading sleep and nutrition experts identified certain vitamins and minerals that can enhance sleep quality.
  • Formulation considerations included minimizing bloating and digestive issues related to lactose intolerance, production of serotonin and melatonin to support sleep, muscle relaxation and craving satisfaction.
  • Likewise, management successfully initiated a retail pilot of Nightfood in the lobby grab-and-go shops of a global hotel group.
  • Nightfood is the perfect food for nighttime snacking and the perfect vehicle for uncharted long-term growth.

Clinical Genomics Announces Three Poster Presentations at ASCO 2021 Annual Meeting, Including New Data Highlighting Clinical Utility of COLVERA® Liquid Biopsy for Colorectal Cancer Recurrence Detection and Prediction of Clinical Outcomes

Retrieved on: 
Monday, June 14, 2021
Clinical medicine, Medicine, Branches of biology, Oncology, Anatomical pathology, DNA, Medical signs, Infectious causes of cancer, Circulating tumor DNA, Colorectal cancer, Assay

COLVERA is a first of its kind blood test to detect circulating tumor DNA for MRD assessment and recurrence monitoring.

Key Points: 
  • COLVERA is a first of its kind blood test to detect circulating tumor DNA for MRD assessment and recurrence monitoring.
  • With these improvements, COLVERA differentiates more accurately between patients with and without recurrent disease, and thus is clinically more informative.
  • https://meetings.asco.org/abstracts-presentations/196522
    Included two cohorts of CRC patients (N=322 and N=144) evaluating the impact of optimizing the assays actionability for CRC recurrence detection.
  • Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer.

Genialis Expands Support for Clinical Biomarker Discovery Platform

Retrieved on: 
Thursday, June 10, 2021
Software, Research, Other Health, Pharmaceutical, Data management, Oncology, Technology, Genetics, Clinical trials, Science, Biotechnology, Health, Other Science, Branches of biology, Biology, Life sciences, Biomarkers, Clinical research, Medical statistics, Biotechnology, Medical signs, Clinical trial, Clinical endpoint

Genialis' AI-enabled biomarker discovery platform serves as an end-to-end solution that de-risks clinical development, but also drives early discovery and supports translational investigations.

Key Points: 
  • Genialis' AI-enabled biomarker discovery platform serves as an end-to-end solution that de-risks clinical development, but also drives early discovery and supports translational investigations.
  • Genialis platform helps address the problem of high clinical trial failure rates and long and expensive R&D slogs.
  • Now, we are most excited about using our biomarker platform to help bridge from successful early discovery to translational evidence to improved clinical outcomes.
  • To bolster its support of clinical biomarker collaborations, Genialis has added two domain experts to its team of applied scientists and alliance managers.